Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 339

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 339
---
 • |     | our ability to complete investigational new drug (“IND”) application enabling studies and successfully                                                                                                                         
 submit INDs or IND supplements or comparable applications, which become effective without any objections by the FDA or comparable regulatory authorities before commencing a clinical trial for any future product candidates; |

| • |     | establishing and maintaining relationships with contract research organizations (“CROs”) and clinical                          
 sites for the clinical development of FYARRO in other indications and any other future product candidates that we may develop; |

| • |     | timely receipt of regulatory approvals from applicable regulatory authorities for any product candidates for 
 which we successfully complete clinical development;                                                         |

| • |     | developing or contracting for an efficient and scalable manufacturing process for future product candidates, 
 including obtaining finished products that are appropriately packaged for sale;                              |

| • |     | negotiating and maintaining an adequate price for FYARRO or any future product candidates, both in the United 
 States and in foreign countries where our products are commercialized;                                        |

| • |     | a continued acceptable safety profile following any regulatory approval of product candidates; |

| • |     | commercial acceptance of product candidates by patients, the medical community and third-party payors; |

| • |     | obtaining coverage and adequate reimbursement by third-party payors for FYARRO or any future product candidates; |

| • |     | satisfying any required post-regulatory approval commitments to applicable regulatory authorities; |

- 233 -

| • |     | identifying, assessing and developing new product candidates; |

| • |     | obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both 
 in the United States and internationally;                                                                        |

| • |     | protecting our rights in our intellectual property portfolio; |

| • |     | defending against third-party interference or infringement claims, if any; |

| • |     | entering into and maintaining, on favorable terms, any collaboration, licensing or other arrangements that may be 
 necessary or desirable to develop, manufacture or commercialize FYARRO and any future product candidates; and     |

| • |     | addressing any competing therapies and technological and market developments and attracting, hiring and retaining 
 qualified personnel.                                                                                              |

We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable